Skip to content

EtiraRX

2 viewers · 30d

Total raised

$2.3M

+$2.3M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $2.3M
ROUNDS
1
INVESTORS
21
FOUNDED
N/A
HQ
Dallas, TX
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Etira, formerly etiraRx, is a Dallas-based clinical-stage oncology company developing small-molecule therapies for therapy-resistant and metastatic cancers. Its approach targets cancer in a way that is not dependent on how much or how often tumor cells mutate, aiming to overcome the tumor heterogeneity that defeats mutation-specific drugs. Lead candidate ERX-315 is in Phase 1 in patients with advanced, unresectable or metastatic solid tumors, with additional programs in ovarian, pancreatic and ER-positive metastatic breast cancer. The company was founded in 2018 and operates from Pegasus Park in Dallas, Texas.

What sets it apart

Rather than targeting a specific mutation, Etira's compounds are designed to kill cancer cells regardless of how they mutate or morph, positioning them for patients whose tumors have already become resistant to standard therapy.

Funding history

1 round
EquityApr 17, 2026
Form D
+$2.3M$2.3M total

Latest SEC filings

via EDGAR · CIK 0001996442
Form D · Apr 17, 2026View on EDGAR

Products

1 tracked

ERX-315

Clinical-stage oncology therapeutic

An investigational oral small-molecule cancer therapeutic in Phase 1, enrolling adult patients with advanced, unresectable and/or metastatic solid tumors including breast, ovarian, pancreatic and endometrial cancer and hepatocellular carcinoma, for whom standard therapies are ineffective or unavailable.

  • Phase 1 clinical stage
  • Oral small molecule
  • Targets advanced, unresectable and metastatic solid tumors
  • Mechanism intended to be independent of tumor mutation status

Links

WebsiteLinkedInSEC EDGAR filings